Teclison Announces Publication of Phase 1 Data Demonstrating the Safety and Therapeutic Potential of Tirapazamine Chemoembolization for Patients with Unresectable Liver Cancer — Tirapazamine (TPZ) with conventional trans-arterial chemoembolization had a good safety profile and promising efficacy signals in early- and intermediate-stage liver cancer, including in patients...

Teclison Completes $5.9 Million Capital Raise Led by W.T.T. Investment, the family office of Taiwan’s Tsai familyProceeds to Advance Clinical Studies of its Potential First-in-Class Therapeutic Agent with Embolization Therapy in Metastatic Solid...

Teclison Announces the Appointment of Wan Lung Eng as Chief Financial Officer PRINCETON, N.J., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Teclison, a clinical-stage pharmaceutical company developing novel cancer therapeutics to induce targeted necrosis of solid tumors and convert the...